InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.590
+0.390 (32.50%)
At close: Apr 17, 2026, 4:00 PM EDT
1.610
+0.020 (1.26%)
After-hours: Apr 17, 2026, 5:57 PM EDT
InflaRx Employees
InflaRx had 65 employees as of December 31, 2025. The number of employees decreased by 9 or -12.16% compared to the previous year.
Employees
65
Change (1Y)
-9
Growth (1Y)
-12.16%
Revenue / Employee
$530
Profits / Employee
-$824,302
Market Cap
114.95M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 65 | -9 | -12.16% |
| Dec 31, 2024 | 74 | 12 | 18.97% |
| Dec 31, 2023 | 62 | 18 | 40.41% |
| Dec 31, 2022 | 44 | -12 | -20.75% |
| Dec 31, 2021 | 56 | 9 | 18.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fractyl Health | 100 |
| PolyPid | 75 |
| Rani Therapeutics Holdings | 71 |
| Seres Therapeutics | 66 |
| aTyr Pharma | 60 |
| Pliant Therapeutics | 49 |
| NeurAxis | 24 |
| Gain Therapeutics | 21 |
IFRX News
- 8 days ago - InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor - GlobeNewsWire
- 17 days ago - InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - GlobeNewsWire
- 18 days ago - InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 4 weeks ago - InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - GlobeNewsWire
- 4 weeks ago - InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 5 weeks ago - InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 5 weeks ago - InflaRx to Report Full Year 2025 Results on March 19, 2026 - GlobeNewsWire
- 7 weeks ago - InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference - GlobeNewsWire